company background image
J

Lotus Ventures CNSX:J Stock Report

Last Price

CA$0.06

Market Cap

CA$5.4m

7D

0%

1Y

-58.6%

Updated

12 Aug, 2022

Data

Company Financials
J fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

J Stock Overview

Lotus Ventures Inc. engages in the production, cultivation, and sale of cannabis products for medical purpose in Canada.

Lotus Ventures Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lotus Ventures
Historical stock prices
Current Share PriceCA$0.06
52 Week HighCA$0.15
52 Week LowCA$0.05
Beta0.56
1 Month Change-7.69%
3 Month Change-14.29%
1 Year Change-58.62%
3 Year Change-65.71%
5 Year Change-82.09%
Change since IPO-64.71%

Recent News & Updates

Mar 29
Subdued Growth No Barrier To Lotus Ventures Inc. (CSE:J) With Shares Advancing 42%

Subdued Growth No Barrier To Lotus Ventures Inc. (CSE:J) With Shares Advancing 42%

Lotus Ventures Inc. ( CSE:J ) shares have had a really impressive month, gaining 42% after a shaky period beforehand...

Shareholder Returns

JCA PharmaceuticalsCA Market
7D0%3.2%3.0%
1Y-58.6%-64.0%0.7%

Return vs Industry: J exceeded the Canadian Pharmaceuticals industry which returned -65% over the past year.

Return vs Market: J underperformed the Canadian Market which returned -0.2% over the past year.

Price Volatility

Is J's price volatile compared to industry and market?
J volatility
J Average Weekly Movement14.9%
Pharmaceuticals Industry Average Movement12.6%
Market Average Movement10.6%
10% most volatile stocks in CA Market19.0%
10% least volatile stocks in CA Market4.3%

Stable Share Price: J is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: J's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2007n/aDale McClanaghanhttps://www.lotuscannabis.ca

Lotus Ventures Inc. engages in the production, cultivation, and sale of cannabis products for medical purpose in Canada. The company sells its products under the Lotus Cannabis Co. brand name. Lotus Ventures Inc. was incorporated in 2007 and is based in Vancouver, Canada.

Lotus Ventures Fundamentals Summary

How do Lotus Ventures's earnings and revenue compare to its market cap?
J fundamental statistics
Market CapCA$5.40m
Earnings (TTM)CA$180.47k
Revenue (TTM)CA$2.48m

30.0x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
J income statement (TTM)
RevenueCA$2.48m
Cost of RevenueCA$984.90k
Gross ProfitCA$1.49m
Other ExpensesCA$1.31m
EarningsCA$180.47k

Last Reported Earnings

May 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.002
Gross Margin60.22%
Net Profit Margin7.29%
Debt/Equity Ratio5.4%

How did J perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is J undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for J?

Other financial metrics that can be useful for relative valuation.

J key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA8.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does J's PE Ratio compare to its peers?

J PE Ratio vs Peers
The above table shows the PE ratio for J vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20.8x
GRIN Grown Rogue International
23.1xn/aCA$16.2m
AYUR Ayurcann Holdings
29x138.3%CA$11.6m
EAST EastWest Bioscience
28xn/aCA$3.0m
CXXI C21 Investments
3.1xn/aCA$43.8m
J Lotus Ventures
30xn/aCA$5.4m

Price-To-Earnings vs Peers: J is expensive based on its Price-To-Earnings Ratio (30x) compared to the peer average (20.8x).


Price to Earnings Ratio vs Industry

How does J's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

Price-To-Earnings vs Industry: J is expensive based on its Price-To-Earnings Ratio (30x) compared to the Canadian Pharmaceuticals industry average (16.1x)


Price to Earnings Ratio vs Fair Ratio

What is J's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

J PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate J's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of J when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate J's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate J's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Lotus Ventures forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


76.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lotus Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of J’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Lotus Ventures competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Lotus Ventures performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


45.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: J has a large one-off gain of CA$157.9K impacting its May 31 2022 financial results.

Growing Profit Margin: J became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: J has become profitable over the past 5 years, growing earnings by 45.1% per year.

Accelerating Growth: J has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: J has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (72.5%).


Return on Equity

High ROE: J's Return on Equity (1.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Lotus Ventures's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: J's short term assets (CA$4.7M) exceed its short term liabilities (CA$1.7M).

Long Term Liabilities: J has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: J's net debt to equity ratio (5.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if J's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: J's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: J's interest payments on its debt are not well covered by EBIT (2.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Lotus Ventures's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate J's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate J's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if J's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if J's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as J has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Dale McClanaghan (66 yo)

7.75yrs

Tenure

CA$205,033

Compensation

Mr. Dale Bernard McClanaghan, MBA has been the Chief Executive Officer and President of Lotus Ventures Inc. since November 27, 2014. Mr. McClanaghan has been the Chief Executive Officer of BCM Resources Co...


CEO Compensation Analysis

Compensation vs Market: Dale's total compensation ($USD160.24K) is about average for companies of similar size in the Canadian market ($USD188.05K).

Compensation vs Earnings: Dale's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: J's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: J's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: J insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lotus Ventures Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lotus Ventures Inc.
  • Ticker: J
  • Exchange: CNSX
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$5.398m
  • Shares outstanding: 89.97m
  • Website: https://www.lotuscannabis.ca

Location

  • Lotus Ventures Inc.
  • 1030 West Georgia Street
  • Suite 1010
  • Vancouver
  • British Columbia
  • V6E 2Y3
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/05/31
Annual Earnings2021/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.